We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » ICER Panel Weighs in on Two Expensive but Useful Myasthenia Gravis Therapies
ICER Panel Weighs in on Two Expensive but Useful Myasthenia Gravis Therapies
The Institute for Clinical and Economic Review (ICER) issued its final word on two treatments for the autoimmune disease Myasthenia Gravis (MG), saying both are useful medically but need colossal price reductions in order to make them at all affordable.